NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CNS(中樞神經系統)治療藥的全球市場:2018年∼2022年

Global CNS Therapeutics Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 650437
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
CNS(中樞神經系統)治療藥的全球市場:2018年∼2022年 Global CNS Therapeutics Market 2018-2022
出版日期: 2018年05月30日內容資訊: 英文 104 Pages
簡介

關於CNS(中樞神經系統)治療藥

CNS治療,適用於影響腦或脊髓結構或功能的中樞神經系統疾病,如帕金森式症,癲癇,阿茨海默症,焦慮症,憂鬱症和躁鬱症。

Technavio的分析師預測,從2018年到2022年之間,CNSR(中樞神經系統)治療藥市場將以4.36%的年複合成長率成長。

本報告提供全球CNS(中樞神經系統)治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第5章 市場規模

  • 市場定義
  • 市場規模(2017年)
  • 市場規模及預測(2017-2022年)

第6章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情形

第7章 客戶形勢

第8章 市場區隔:各終端用戶

  • 市場區隔:各終端用戶(2017-2022年)
  • 比較:各終端用戶
  • MHD - 市場規模與預測
  • NDDs - 市場規模與預測
  • 其他 - 市場規模與預測
  • 市場機會:各終端用戶

第9章 地區形勢

  • 各地區市場區隔(2017-2022年)
  • 地區比較
  • 南北美洲 - 市場規模與預測
  • 歐洲、中東、非洲地區 - 市場規模與預測
  • 亞太地區 - 市場規模與預測
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 自覺計劃的增加
  • 新世代藥物的採用增加
  • 精神障礙治療的技術進步

第13章 業者情勢

  • 概要
  • 創造性破壞狀況

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis

第15章 附錄

  • 簡稱的清單
目錄
Product Code: IRTNTR23068

About CNS therapeutics

CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson's disease, epilepsy, Alzheimer's disease, anxiety, depression, and bipolar disorders.

Technavio's analysts forecast the Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the CNS therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics for CNS disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global CNS Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis

Market driver

  • Increasing prevalence of mental illness
  • For a full, detailed list, view our report

Market challenge

  • Side effects of CNS therapeutics
  • For a full, detailed list, view our report

Market trend

  • Increased adoption of new-generation drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY END-USER

  • Segmentation by end-user
  • Comparison by end-user
  • MHDs - Market size and forecast 2017-2022
  • NDDs - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by end-user

PART 09: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Increasing awareness programs
  • Increased adoption of new-generation drugs
  • Advances in technology in treating mental disorders

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis

PART 15: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global healthcare market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2017
  • Exhibit 18: Customer landscape
  • Exhibit 19: End-user - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by end-user
  • Exhibit 21: MHDs - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: MHDs - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: NDDs - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: NDDs - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Others - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Others - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Market opportunity by end-user
  • Exhibit 28: Global - Market share by geography 2017-2022 (%)
  • Exhibit 29: Regional comparison
  • Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 32: EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 33: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 34: APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Rise in population aged 65 and above (% of total)
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: Eli Lilly: Overview
  • Exhibit 45: Eli Lilly: Business segments
  • Exhibit 46: Eli Lilly: Organizational developments
  • Exhibit 47: Eli Lilly: Geographic focus
  • Exhibit 48: Eli Lilly- Segment focus
  • Exhibit 49: Eli Lilly: Key offerings
  • Exhibit 50: F. Hoffmann-La Roche overview
  • Exhibit 51: F. Hoffmann-La Roche- Business segments
  • Exhibit 52: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 53: F. Hoffmann-La Roche- Geographic focus
  • Exhibit 54: F. Hoffmann-La Roche- Segment focus
  • Exhibit 55: F. Hoffmann-La Roche - Key offerings
  • Exhibit 56: Johnson & Johnson overview
  • Exhibit 57: Johnson & Johnson- Business segments
  • Exhibit 58: Johnson & Johnson- Organizational developments
  • Exhibit 59: Johnson & Johnson- Geographic focus
  • Exhibit 60: Johnson & Johnson- Segment focus
  • Exhibit 61: Johnson & Johnson- Key offerings
  • Exhibit 62: Merck: Overview
  • Exhibit 63: Merck: Business segments
  • Exhibit 64: Merck: Organizational developments
  • Exhibit 65: Merck: Geographic focus
  • Exhibit 66: Merck - Segment focus
  • Exhibit 67: Merck-Key offerings
  • Exhibit 68: Novartis: Overview
  • Exhibit 69: Novartis: Business segments
  • Exhibit 70: Novartis: Organizational developments
  • Exhibit 71: Novartis: Geographic focus
  • Exhibit 72: Novartis - Segment focus
  • Exhibit 73: Novartis-Key offerings